A comparison between placental and amniotic mesenchymal stem cells for transamniotic stem cell therapy (TRASCET) in experimental spina bifida
A comparison between placental and amniotic mesenchymal stem cells for transamniotic stem cell therapy (TRASCET) in experimental spina bifida
复制标题
DOI：
10.1016/j.jpedsurg.2016.02.071
复制
发表时间：
2016-06-01
影响因子：
2.4
通讯作者：
Fauza, Dario O.
中科院分区：
文献类型：
--
作者：
Feng, Christina;Graham, Christopher D.;Fauza, Dario O.
目的：我们比较了胎盘来源和羊水来源的间充质干细胞（pMSCs和afMSCs，分别）在transamniotic干细胞疗法（TRASCET）的实验性脊柱裂。方法：妊娠母鼠（n = 29）暴露于维甲酸诱导胎儿脊柱裂分为四组。三组在妊娠第17天（足月= 21-22天）接受体积匹配的羊膜内注射生理盐水（n = 38个胎儿）或2 x 106个细胞/mL的同基因标记afMSC（n = 73）或pMSC（n = 115）悬浮液。未处理的胎儿作为对照。动物在分娩前被杀死。通过Fisher精确检验进行统计学比较（p < 0.05）。结果：各治疗组的存活率相似（p = 0.08）。在患有孤立性脊柱裂的胎儿（n = 100）中，与盐水和未处理组相比，afMSC和pMSC组中的缺陷覆盖（部分或完全）百分比更高（成对比较中p < 0.001-0.03）。afMSC和pMSC组之间的覆盖率（p = 0.94）或生理盐水和未处理组之间的覆盖率（p = 0.98）没有差异。结论：在啮齿动物模型中，pMSC和afMSC在浓缩羊膜内注射后都可以诱导可比较的实验性脊柱裂的覆盖率。这拓宽了TRASCET作为脊柱裂产前治疗的潜在替代方案的时机和细胞来源的选择。(C)2016 Elsevier Inc. All rights reserved.
Purpose: We compared placental-derived and amniotic fluid-derived mesenchymal stem cells (pMSCs and afMSCs, respectively) in transamniotic stem cell therapy (TRASCET) for experimental spina bifida.Methods: Pregnant dams (n = 29) exposed to retinoic acid for the induction of fetal spina bifida were divided into four groups. Three groups received volume-matched intraamniotic injections of either saline (n = 38 fetuses) or a suspension of 2 x 10(6) cells/mL of syngeneic, labeled afMSCs (n = 73) or pMSCs (n = 115) on gestational day 17 (term = 21-22 days). Untreated fetuses served as controls. Animals were killed before term. Statistical comparisons were by Fisher's exact test (p < 0.05).Results: Survival was similar across treatment groups (p = 0.08). In fetuses with isolated spina bifida (n = 100), there were higher percentages of defect coverage (either partial or complete) in both afMSC and pMSC groups compared with saline and untreated groups (p < 0.001-0.03 in pairwise comparisons). There were no differences in coverage rates between afMSC and pMSC groups (p = 0.94) or between saline and untreated groups (p = 0.98).Conclusions: Both pMSC and afMSC can induce comparable rates of coverage of experimental spina bifida after concentrated intraamniotic injection in the rodent model. This broadens the options for timing and cell source for TRASCET as a potential alternative in the prenatal management of spina bifida. (C) 2016 Elsevier Inc. All rights reserved.